The Medical Research Institute of New Zealand (MRINZ) plans to launch a multi-country clinical study, called Novel START, using Adherium’s connected inhalers, which have both a CE Mark and FDA 510(k) clearance. In addition to New Zealand, the study will include participants from Australia, the United Kingdom and Italy.
Adherium’s Smartinhalers send data on when medication was taken to connected devices via Bluetooth. The platform helps patients, caregivers, and physicians remotely monitor and manage patients’ adherence to their medication.
Researchers plan to recruit 675 adults to investigate the safety and efficacy of three different treatment regimens for mild asthma: 1) a combination of inhaled corticosteroid (ICS) and long acting beta agonist (LABA); 2) short acting beta agonist (SABA); and 3) regular use of ICS and SABA as needed.
“The data collected in the Novel START study will be used as part of the primary outcome analysis to determine the optimal management regimen in mild asthma,” MRINZ Director Richard Beasly said in a statement.
For the study, Adherium will supply the Medical Research Institute of New Zealand with 5,700 Smartinhaler devices and its Smartinhaler Live system.Adherium will supply MRINZ with 5,700 Smartinhaler devices and its Smartinhaler Live system that will help researchers monitor study participants. The study is expected to run for one year.
“Clinical projects such as this major study being conducted by MRINZ are important to Adherium’s business,” Adherium Group CEO Garth Sutherland said in a statement. “In addition to the revenue they provide, clinical projects such as this validate our ever-improving technology.”
Last year, we’ve seen Adherium making a deal with AstraZeneca to incorporate its products and services into AstraZeneca’s patient support programs for people with COPD and asthma. A few months later, the company raised $25.6 million ($35 million AU) in an IPO on the Australian Securities Exchange, including a $3 million investment from AstraZeneca.